Clinical Trial Detail

NCT ID NCT03263429
Title Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Vanderbilt-Ingram Cancer Center
Indications

colorectal cancer

Therapies

Irinotecan + Panitumumab + Telaglenastat

Age Groups: adult senior

No variant requirements are available.